Cargando…

Natural Killer Cells: Development, Maturation, and Clinical Utilization

Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Abel, Alex M., Yang, Chao, Thakar, Monica S., Malarkannan, Subramaniam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099181/
https://www.ncbi.nlm.nih.gov/pubmed/30150991
http://dx.doi.org/10.3389/fimmu.2018.01869
_version_ 1783348608574160896
author Abel, Alex M.
Yang, Chao
Thakar, Monica S.
Malarkannan, Subramaniam
author_facet Abel, Alex M.
Yang, Chao
Thakar, Monica S.
Malarkannan, Subramaniam
author_sort Abel, Alex M.
collection PubMed
description Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like receptor and Ly49) to develop, mature, and recognize “self” from “non-self.” The essential roles of common gamma cytokines such as interleukin (IL)-2, IL-7, and IL-15 in the commitment and development of NK cells are well established. However, the critical functions of pro-inflammatory cytokines IL-12, IL-18, IL-27, and IL-35 in the transcriptional-priming of NK cells are only starting to emerge. Recent studies have highlighted multiple shared characteristics between NK cells the adaptive immune lymphocytes. NK cells utilize unique signaling pathways that offer exclusive ways to genetically manipulate to improve their effector functions. Here, we summarize the recent advances made in the understanding of how NK cells develop, mature, and their potential translational use in the clinic.
format Online
Article
Text
id pubmed-6099181
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60991812018-08-27 Natural Killer Cells: Development, Maturation, and Clinical Utilization Abel, Alex M. Yang, Chao Thakar, Monica S. Malarkannan, Subramaniam Front Immunol Immunology Natural killer (NK) cells are the predominant innate lymphocyte subsets that mediate anti-tumor and anti-viral responses, and therefore possess promising clinical utilization. NK cells do not express polymorphic clonotypic receptors and utilize inhibitory receptors (killer immunoglobulin-like receptor and Ly49) to develop, mature, and recognize “self” from “non-self.” The essential roles of common gamma cytokines such as interleukin (IL)-2, IL-7, and IL-15 in the commitment and development of NK cells are well established. However, the critical functions of pro-inflammatory cytokines IL-12, IL-18, IL-27, and IL-35 in the transcriptional-priming of NK cells are only starting to emerge. Recent studies have highlighted multiple shared characteristics between NK cells the adaptive immune lymphocytes. NK cells utilize unique signaling pathways that offer exclusive ways to genetically manipulate to improve their effector functions. Here, we summarize the recent advances made in the understanding of how NK cells develop, mature, and their potential translational use in the clinic. Frontiers Media S.A. 2018-08-13 /pmc/articles/PMC6099181/ /pubmed/30150991 http://dx.doi.org/10.3389/fimmu.2018.01869 Text en Copyright © 2018 Abel, Yang, Thakar and Malarkannan. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Abel, Alex M.
Yang, Chao
Thakar, Monica S.
Malarkannan, Subramaniam
Natural Killer Cells: Development, Maturation, and Clinical Utilization
title Natural Killer Cells: Development, Maturation, and Clinical Utilization
title_full Natural Killer Cells: Development, Maturation, and Clinical Utilization
title_fullStr Natural Killer Cells: Development, Maturation, and Clinical Utilization
title_full_unstemmed Natural Killer Cells: Development, Maturation, and Clinical Utilization
title_short Natural Killer Cells: Development, Maturation, and Clinical Utilization
title_sort natural killer cells: development, maturation, and clinical utilization
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099181/
https://www.ncbi.nlm.nih.gov/pubmed/30150991
http://dx.doi.org/10.3389/fimmu.2018.01869
work_keys_str_mv AT abelalexm naturalkillercellsdevelopmentmaturationandclinicalutilization
AT yangchao naturalkillercellsdevelopmentmaturationandclinicalutilization
AT thakarmonicas naturalkillercellsdevelopmentmaturationandclinicalutilization
AT malarkannansubramaniam naturalkillercellsdevelopmentmaturationandclinicalutilization